ABSTRACT We tested the hypothesis that the changes in free fatty acid and ac-glycoprotein concentrations, which occur during acute myocardial infarction, exert asynchronous and opposing influences on the serum protein binding of selected drugs. Free drug fractions of two antiarrhythmic agents with contrasting binding characteristics, quinidine and procainamide, were related to free fatty acid and a I-glycoprotein concentrations on days 1 through 5 and 10 in 20 patients with acute myocardial infarction. The mean free quinidine fraction was elevated on day 1 (9.0 + 4.4% vs 6.7 +-2.7% in patients with stable heart disease; p < .05) and fell progressively to day 10 (4.0 + 2.8%; p < .0002) as free fatty acid concentration decreased (day 1 = 464 ± 272 meq/liter; day 10 264 +-155 meq/liter; p < .01) and ct-glycoprotein concentration increased (day 1 98 + 31 mg/dl; day 10 = 141 + 47 mg/dl; p < .02). Multiple stepwise regression showed a major influence of changing ac-glycoprotein concentration on the observed sequential changes in the free quinidine fraction (p < .005). In contrast, no serial changes il procainamide binding were noted. In conclusion, metabolic changes during the course of acute myocardial infarction sequentially alter free quinidine fraction and, consequently, may influence pharmacodynamics. Circulation 70, No. 3, 472-478, 1984. ANTIARRHYTHMIC THERAPY is commonly used during the course of acute myocardial infarction for prophylaxis or treatment of "warning" arrhythmias, treatment of established ventricular tachycardia or fibrillation, or control of convalescent arrhythmias. Determination of the appropriate dosage of antiarrhythmic drug is usually guided by the knowledge of the pharmacologic properties of the drug in the particular clinical setting. Therefore, although treatment 
ANTIARRHYTHMIC THERAPY is commonly used during the course of acute myocardial infarction for prophylaxis or treatment of "warning" arrhythmias, treatment of established ventricular tachycardia or fibrillation, or control of convalescent arrhythmias. Determination of the appropriate dosage of antiarrhythmic drug is usually guided by the knowledge of the pharmacologic properties of the drug in the particular clinical setting. Therefore, although treatment of such patients often appears empiric, with ectopy suppression as the major end point, dosage guidelines have been derived from prior experimentation and modeling of pharmacokinetics. For instance, altered elimination of both lidocaine and procainamide have been documented in patients with congestive heart failure, 2 and the altered serum protein binding of lidocaine during the first 72 hr of acute myocardial infarction that results from increasing ao-glycoprotein concentrations provides an explanation of lidocaine accumulation in some patients. 3 Knowledge of such changes in binding are necessary to explain relative drug activity (i.e., normal lidocaine activity with increased total drug concentration) in the acute infarction setting.
The changes in drug binding that occur as the patient enters the late hospital and early posthospital period after acute myocardial infarction have been less well studied. If, during this period of time, drug binding continues to vary dynamically, knowledge of influences on free drug concentration may be necessary for the appropriate interpretatioii of drug response and plasma concentrations and for the prediction of success of long-term therapy with respect to drug efficacy and toxicity.
To assess potential changes in drug binding during both the early and late hospital phases of acute myocardial infarction, c, -glycoprotein and free fatty acid concentrations, the major metabolic parameters modulating serum protein binding, were serially measured, along with serum protein binding of two model anti-THERAPY AND PREVENTION-PHARMACOLOGY arrhythmic drugs with different binding characteristics: (1) quinidine, a highly bound drug, the binding of which is dependent on the concentrations of both aglycoprotein4 and free fatty acids' 6 and (2) procainamide, a poorly bound drug, the binding of which has no known dependence on a I-glycoprotein or free fatty acid concentrations.
Methods
Patient selection. The study group consisted of 20 patients admitted to the Coronary Care Unit at Jackson Memorial Hospital with acute myocardial infarction. The diagnosis of myocardial infarction required the presence of two or more of the following: (1) typical history of prolonged cardiac pain resistant to nitroglycerin therapy and rest, (2) electrocardiographic changes indicative of acute myocardial infarction with characteristic serial ST-T wave changes and new q waves, (3) abnormalities in creatine kinase-MB levels, and (4) results of technetium pyrophosphate scanning typical of transmural myocardial infarction. Patients were classified according to the presence or absence of congestive heart failure, hypotension, or life-threatening arrhythmias, and according to whether heparin (full or low dose) was administered. None of the patients had intrinsic abnormalities in hepatic or renal function or abnormal serum albumin concentrations at the time of admission or discharge. Eight patients (40%) received lidocaine within the first 36 hr of hospitalization and four patients (20%) received propranolol at some time during the study period. The clinical characteristics of the study patients are summarized in table 1.
Laboratory analysis. Venous blood samples were obtained with patients in the fasting state on days 1 through 5 and 10 of hospitalization. Blood was collected by a standard venipuncture technique into glass syringes without the addition of heparin or into Vacutainer tubes, which do not influence the serum concentration or binding of quinidine or procainamide.5 7 Samples were transferred to the laboratory and centrifuged immediately. a,-Glycoprotein concentrations were measured by radial immunodiffusiont with a commercially available kit (M-partigen; Calbiochem-Behring Corp.). Free fatty acid concentrations were determined by the colorimeter method of Itaya.9 Drug binding was measured after the addition of quinidine sulfate (2 gg/ml) or procainamide hydrochloride (5 gg/ml) in vitro. Free quinidine and procainamide concentrations were determined by ultrafiltration.5 Total and free quinidine concentrations were measured by gas-liquid chromatography with the use of nitrogen-phosphorus-sensitive detector,7 and the free drug fraction was calculated. The within-and between-run precision for the quinidine test averaged 3.8% and 4.3% and that for the procainamide test averaged 3.7% and 3.3%. The standard error of the determination of unbound drug fraction by ultrafiltration was less than 5% of the determined value.
Statistical analysis. Measurements that were not well replicated were excluded from the data analysis (this is reflected in the observations as listed in table 2). The daily free quinidine fractions in patients in this study were compared with a mean level of 6.7 ± 2.7% measured in a series of 34 patients with stable coronary artery disease by the two-tailed t test. Changes over time were tested for significance with the two-tailed t test corrected for multiple comparisons by the Bonferroni method. The association of free quinidine fraction to a1-glycoprotein concentration among patients was examined by the analysis of variance of free quinidine fraction with a1-glycoprotein level as the covariate. The slopes of the within-patient regression lines were tested for homogeneity and the pooled within-patient slope was estimated. The differences among the means for the patients, adjusted for differences in a1-glycoprotein concentration, were tested for significance. The dynamics of changing free quinidine fractions were assessed by multiple stepwise regression to estimate the daily change in free quinidine fraction and a1-glycoprotein and free fatty acid concentrations.
Validation of binding determinations in vivo. The binding technique in vitro (drug added to serum) was validated in a comparison to conditions in vivo (drug administered to patient). In 10 patients with arrhythmias, quinidine binding measured 5.7 + 2.7% (mean ± SD) at 2 pgg/ml by the technique in vitro compared with 4.6 + 2.5% (NS) when similar concentrations were reached after oral drug administration. Procainamide binding measured 66 ± 5% at 5 gg/ml in vitro compared with 68 ± 6% (NS; n = 10) when similar concentrations were reached after drug administration. Unbound drug fractions in vitro and in vivo correlated significantly for both quinidine (r = .76, p < .01) and procainamide (r = .79, p < .01).
Normal reference values. The following reference ("normal") values were obtained in patients with stable coronary artery disease whose ages were similar to those of patients in the acute myocardial infarction group: unbound quinidine fraction 6.7 ± 2.7% (n = 34), unbound procainamide fraction 68 + 9% (n=20), a1-glycoprotein concentration 61 ± 21 mg/dl (n = 14). These patients had typical angina or coronary artery disease diagnosed at catheterization and had not sustained an acute myocardial infarction (by criteria above) within the 3 months before these determinations. These patients were receiving propranolol (60%), nitrates (8 1%) , lidocaine (0%), and calcium channel-blocking agents (0%).
Results
Acute myocardial infarction group. Free fatty acid concentrations (table 2) averaged 464 ± 272 meq/liter on admission (within 24 hr of the onset of symptoms). These levels then fell progressively from day 1 through day 10, despite the use of low-dose heparin on days 2 through 5 in 10 of the 20 patients. Free fatty acid concentrations on day 10 averaged 264 ± 155 meq/ liter. These values were significantly lower than admission values (p < .01; figure 1 ). a 1-Glycoprotein concentrations (figure 2) were somewhat higher than control values, but not significantly increased on admission (98 + 31 mg/dl), and rose on day 2 (115 + 37 mg/dl; p < .001) and day 3 (139 ± 35 mg/dl; p < .001), reaching an elevated plateau that was maintained through day 10. Day 5 and 10 values were significantly elevated compared with the admission values (p < .0002 and p < .02, respectively).
Free quinidine fraction (figure 3) measured in admission blood samples from patients with acute myocardial infarction averaged 9.0 + 4.4%, a value significantly higher than the 6.7 ± 2.7% in patients with stable coronary artery disease (p < .05). The free quinidine fraction in patients with myocardial infarction decreased significantly on day 2 (5.6 + 2.5%; p < .001) and day 3 (4.2 + 2.4%; p < .035), reaching a plateau level of 4.2 ± 2.4% that was essentially maintained through day 10. The mean free quinidine fraction was significantly reduced on days 5 and 10 when compared with admission values (p < .0002) and the mean free fractions on days 3, 4, 5, and 10 were significantly lower than the mean value for patients with stable coronary artery disease (p < .01).
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Free procainamide fraction (figure 4) At this point, R2 = .64, i.e. 64% of the variability of the free quinidine fraction was accounted for. The addition of free fatty acid and changes in free fatty acid concentration added no'statistically significant information to this relationship (change in R2 _ .001). The strong negative relationship of the change in free quinidine fraction to the previous'day's free drug fraction means that larger changes (decreases) in free drug fractions were associated with higher free drug fractions on the previous day. 
Discussion
Acute myocardial infarction has provided a clinical model for the study of dynamic changes in free drug fraction consequent to a pathophysiologic process. During the first 24 hr after the onset of myocardial infarction, catecholamine concentrations increase, and there is a secondary increase in free fatty acid concentration.t0 Free fatty acids have been previously shown to compete with drugs for binding sites on serum albumin. For example, the serum protein binding of quinidine, propranolol, and diazepam is decreased by heparin-induced increases in free fatty concentrations.5,6, 11 However, the biologic significance of such changes in free drug fraction, and the relationship of changes in free fatty acid concentrations to drug binding in other clinical settings, remains uncertain. An additional metabolic change pertinent to drug binding occurs subsequent to the first 24 hr of acute myocardial infarction. During this time period increases in a,-glycoprotein occur and they have been associated with increases in the serum protein binding of imipramine, lidocaine, and disopyramide.3 2 13 These asynchronous and opposing pathophysiologic influences on drug binding led to the hypothesis that drugs highly bound to plasma protein, including a,-glycoprotein binding sites, might demonstrate a biphasic relationship between free and total drug concentration during the course of myocardial infarction. Specifically, decreased binding (increased free drug fraction) might occur early in the course of infarction due to the competitive influence of increased concentrations of free fatty acids and increased binding (decreased free drug fraction) mediated by increased binding sites on a,-glycoprotein might be present for some time thereafter. Definition of the magnitude and time course of such changes in drug binding was the major goal of these studies.
We used quinidine as a model of a highly bound, chemically basic drug that binds to both albumin and a,-glycoprotein sites. Increases in free quinidine fraction have previously been demonstrated as a result of increased free fatty acid concentrations induced by heparin administration during cardiac catheterization or hemodialysis.56 This influence on drug binding of changing free fatty acid concentrations during acute myocardial infarction was indicated in this study by the relatively elevated free quinidine fraction in patients with infarction on admission (9.9 + 3.0%) when compared with the free fraction in patients with stable coronary artery disease (6.7 + 2.7%). However, multiple stepwise regression showed that changes in free fatty acid concentrations were not the major influence on changing free quinidine fractions. Nevertheless, the binding data do indicate that on admission there would be an average 34% relative increase in free quinidine concentration at any given measured total quinidine level in these patients with acute myocardial infarction.
The major dynamic variable influencing free quinidine fraction during the 10 day study period was the progressive change in a,-glycoprotein concentrations, as shown by multiple stepwise regression analysis (p < .005). Indeed, the mean a I-glycoprotein concentration increased by approximately 20% on both days 2 and 3 to reach a plateau value of 140 mg/dl by day 4. The free quinidine fraction showed a parallel decrease (for each mg/dl rise in a, -glycoprotein concentration, there was 0.0588 ± 0.0074 decrease in % free quinidine), establishing a new plateau value for the group of approximately 4% by day 3. At this time there would be an average 46% reduction in free quinidine concentration at any given total quinidine level for the group that would be related to increased binding sites provided by the elevated concentration of a,-glycoprotein. For purposes of comparison, procainamide, a drug not dependent on a,-glycoprotein for binding, was studied. Procainamide binding in the patients was normal on admission and did not change significantly during acute myocardial infarction.
While the mean a,-glycoprotein concentration remained elevated for the entire 10 day observation period, there was large interindividual variability in the time course of changing a,-glycoprotein levels and free quinidine fractions. There were no discernible differences in clinical course, site of infarction, or peak creatinine kinase-MB levels between the groups with normal vs abnormal a, -glycoprotein concentrations on day 10. This may merely reflect our inability to properly assess all of the many factors that result in these changes. In those individuals in whom a,-glycoprotein levels returned to within 10% of their normal baseline value by day 10, the corresponding mean free quinidine fraction was 6.0 ± 3.4%. This finding confirms that 6.7% is a characteristic free quinidine fraction in patients with chronic stable coronary artery disease. In contrast, those nine subjects in whom a,-glycoprotein concentration was within 10% of peak on day 10 had a markedly reduced mean free quinidine fraction of only 1.7 ± 1.3%. Applying these data of interindividual variability to a representative clinical example, a "therapeutic" total quinidine concentration of 4 jig/ ml would represent 0.24 ,ug/ml of free drug in the subjects whose a1-glycoprotein concentrations had returned to baseline, but only 0.07 gg/ml of free drug ( a pure albumin system. Moreover, decreases in albumin concentration would increase unbound quinidine fraction and would counteract, rather than account for, the consistent progressive decrease in unbound quinidine fraction that we observed during the course of infarction. The use of lidocaine and propranolol, which also bind to ao-glycoprotein, was monitored but could not be controlled. Again, any competitive influence on binding would increase rather than decrease amounts of the unbound form and therefore would not account for the observed decreases in unbound quinidine fraction. A competitive influence contributing to the increase in unbound quinidine observed within the first 24 hr of infarction is a possibility. However, this mechanism was considered unlikely since less than half the patients were receiving either of these drugs and a consistent early elevation of unbound quinidine fraction was still seen in the patients with infarction.
The clinical implications of these biphasic changes in quinidine binding during the course of acute myocardial infarction must be considered carefully. These findings indicate that the free drug concentration would be underestimated by measurements of total drug levels near the time of hospital admission and overestimated by measurement later in the hospital course. Although direct assessment of the relationship between the changing free quinidine fraction and potential changes in pharmacodynamics were beyond the scope of the current study, several inferences can be made from related work. First, it is well documented that changes in drug binding may result in changes in pharmacokinetic parameters.5 Furthermore, it is generally accepted, although not adequately documented, that levels of free drug reflect drug activity. Thus, assuming these changes in free drug concentration translate into changes in drug activity, the relationship between total concentration of drug and antiarrhythmic response would be constantly changing during the first 2 weeks after an acute myocardial infarction as a function of dynamic changes in the relationship between free and total drug concentration. Further investigation of the relationship between changing free drug concentrations and antiarrhythmic end points, such as ventricular ectopic suppression, is essential to define the extent of therapeutic importance of these metabolic variables.
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